25I-NBOMe: Difference between revisions

Line 15:

==Pharmacology==

25I-NBOMe has efficacy at the [[serotonin#The 5-HT system|5-HT2A receptor]] where it acts as a superpotent [[Agonist#Agonists|partial agonist]].<ref name="pmid21174090">Ettrup, A. E. A.; Hansen, M.; Santini, M. A.; Paine, J.; Gillings, N.; Palner, M.; Lehel, S.; Herth, M. M.; Madsen, J. (2010). "Radiosynthesis and in vivo evaluation of a series of substituted 11C-phenethylamines as 5-HT2A agonist PET tracers". European Journal of Nuclear Medicine and Molecular Imaging 38 (4): 681–693. (PubMed.gov / NCBI) | http://www.ncbi.nlm.nih.gov/pubmed/21174090</ref> However, the role of these interactions and how they result in the [[psychedelic]] experience ~~continues~~ to remain elusive.

25I-NBOMe has efficacy at the [[serotonin#The 5-HT system|5-HT2A receptor]] where it acts as a superpotent [[Agonist#Agonists|partial agonist]].<ref name="pmid21174090">Ettrup, A. E. A.; Hansen, M.; Santini, M. A.; Paine, J.; Gillings, N.; Palner, M.; Lehel, S.; Herth, M. M.; Madsen, J. (2010). "Radiosynthesis and in vivo evaluation of a series of substituted 11C-phenethylamines as 5-HT2A agonist PET tracers". European Journal of Nuclear Medicine and Molecular Imaging 38 (4): 681–693. (PubMed.gov / NCBI) | http://www.ncbi.nlm.nih.gov/pubmed/21174090</ref> However, the role of these interactions and how they result in the [[psychedelic]] experience continue to remain elusive.

This compound is pharmacologically unique when compared to other psychedelics through its action on [[serotonin]] receptors. It is one of the only [[Agonist#Agonists|full agonists]] for the human [[Serotonin#The 5-HT system|5-HT2A receptor]] receptor in existence.<ref name="pmid21174090" /> In comparison, classical psychedelics such as [[LSD]], [[DMT]] and [[psilocin]] can only be considered [[Agonist#Agonists|partial agonists]].

@@ Line 15: / Line 15: @@
 ==Pharmacology==
 {{Further|Serotonergic psychedelic}}
-I-NBOMe has efficacy at the [[serotonin#The 5-HT system|5-HT<sub>2A</sub> receptor]] where it acts as a superpotent [[Agonist#Agonists|partial agonist]].<ref name="pmid21174090">Ettrup, A. E. A.; Hansen, M.; Santini, M. A.; Paine, J.; Gillings, N.; Palner, M.; Lehel, S.; Herth, M. M.; Madsen, J. (2010). "Radiosynthesis and in vivo evaluation of a series of substituted 11C-phenethylamines as 5-HT2A agonist PET tracers". European Journal of Nuclear Medicine and Molecular Imaging 38 (4): 681–693. (PubMed.gov / NCBI) | http://www.ncbi.nlm.nih.gov/pubmed/21174090</ref> However, the role of these interactions and how they result in the [[psychedelic]] experience continues to remain elusive.
+I-NBOMe has efficacy at the [[serotonin#The 5-HT system|5-HT<sub>2A</sub> receptor]] where it acts as a superpotent [[Agonist#Agonists|partial agonist]].<ref name="pmid21174090">Ettrup, A. E. A.; Hansen, M.; Santini, M. A.; Paine, J.; Gillings, N.; Palner, M.; Lehel, S.; Herth, M. M.; Madsen, J. (2010). "Radiosynthesis and in vivo evaluation of a series of substituted 11C-phenethylamines as 5-HT2A agonist PET tracers". European Journal of Nuclear Medicine and Molecular Imaging 38 (4): 681–693. (PubMed.gov / NCBI) | http://www.ncbi.nlm.nih.gov/pubmed/21174090</ref> However, the role of these interactions and how they result in the [[psychedelic]] experience continue to remain elusive.
 This compound is pharmacologically unique when compared to other psychedelics through its action on [[serotonin]] receptors. It is one of the only [[Agonist#Agonists|full agonists]] for the human [[Serotonin#The 5-HT system|5-HT<sub>2A</sub> receptor]] receptor in existence.<ref name="pmid21174090" /> In comparison, classical psychedelics such as [[LSD]], [[DMT]] and [[psilocin]] can only be considered [[Agonist#Agonists|partial agonists]].